Shilpa Medicare gets USFDA’s nod for Tenofovir Alafenamide tablets

16 Sep 2022 Evaluate

Shilpa Medicare has received U.S Food and Drug Administration tentative (USFDA) approval for its ANDA, Tenofovir Alafenamide Tablets, 25 mg on September 15, 2022. The ANDA was filed as ‘First to File’ submission on NCE -1 date. Tenofovir Alafenamide Tablets, 25 mg is a generic equivalent of reference listed drug (RLD) Vemlidy tablets, of Gilead Sciences Inc. used in the treatment of chronic hepatitis B virus infection as recommended in the label approved by FDA. The US market for Tenofovir Alafenamide Tablets, 25 mg is around $498.14 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

270.65 -2.05 (-0.75%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×